Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul-Aug;15(4):272-275.
doi: 10.1097/ADM.0000000000000762.

DEA Disconnect Leads to Buprenorphine Bottlenecks

Bayla Ostrach  1 , Delesha Carpenter, Larry P Cote
Affiliations
Editorial

DEA Disconnect Leads to Buprenorphine Bottlenecks

Bayla Ostrach et al. J Addict Med. 2021 Jul-Aug.

Abstract

Objectives: To describe a buprenorphine dispensing bottleneck resulting from a pharmacist-perceived Drug Enforcement Administration "cap" on the amount of buprenorphine that can be ordered or stocked.

Methods: Expert review and preliminary fieldwork.

Results: We find no such cap exists, though medication distributors struggle to accurately understand and interpret regulatory guidelines, with implications for medication availability.In states where opioid overdose rates remain higher and efforts to increase the number of eligible health care providers prescribing medications to treat opioid use disorder are underway, patients prescribed buprenorphine products report difficult filling prescriptions and pharmacists perceive limits on how much medication they can order and stock.

Conclusions: We recommend Drug Enforcement Administration policy clarifications or changes to facilitate distributor interpretation; pharmacist workflow; and patient access to medication. We also advise continuing education with pharmacists and buprenorphine prescribers. These steps would facilitate greater access to lifesaving treatment for opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. ACOG. 2018. “Opioid Use and Opioid Use Disorder in Pregnancy - Committee Opinion.” ACOG Committee on Obstetric Practice. ACOG. Available at: https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinio... . Accessed November 28, 2019.
    1. American Pharmacists Association. 2020. Increasing Access to and Advocacy for Medications for Opioid Use Disorder (MOUD). Actions of the 2020 House of Delegates – Special Session. Available at: https://www.pharmacist.com/sites/default/files/audience/2020_Report_of_t... . Accessed August 10, 2020.
    1. Carroll J, Green T, Noonan R. Evidence-Based Strategies for Preventing Opioid Overdose: What's Working in the United States, 2018. Centers for Disease Control; 2018. Available at: https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies... . Accessed December 2, 2019.
    1. Coe MA, Lofwall MR, Walsh SR. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019; 13 (2):93–103.
    1. Cooper HLF, Cloud DH, Freeman PR, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy 2020; 102701DOI 10.1016/j.drugpo.2020.102701. - DOI

Publication types